In the Middle East, various pay-to-prescribe schemes were used to induce healthcare providers to increase their prescriptions of Sanofi products. Charles Cain, FCPA unit chief at US SEC ...

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved ... approval of Merilog to Sanofi (SNY)-Aventis U.S ...

The third new business unit – emerging markets – bundles Sanofi's generic medicines and older products still in patent with the company's consumer healthcare products, emphasising that in ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Sanofi's Sarclisa (isatuximab ... recently gained approval from China’s National Medical Products Administration, in particular for the Sarclisa-VRd combo for treating NDMM individuals who ...